Inflammatory Bowel Disease and Colorectal Cancer Dynamics

Inflammatory bowel disease (IBD), encompassing ulcerative colitis and Crohn’s disease, is characterised by chronic gastrointestinal inflammation that predisposes to colorectal cancer (CRC). Persistent mucosal injury and repair foster genetic and epigenetic alterations, shifting normal epithelium towards dysplasia and neoplasia. Colitis-associated cancer (CAC) follows a distinct evolutionary trajectory from sporadic CRC, with early TP53 mutations, field cancerization in non-dysplastic mucosa and rare shared genetic events between lesions. Chronic inflammation accelerates mutagenesis, promotes lineage plasticity away from canonical Wnt signalling and drives independent tumour clones. Surveillance strategies hinge on recognising cumulative inflammatory burden and identifying molecular biomarkers to stratify risk.

Research from Nature Portfolio

Recent genomic analyses of colitis-associated cancers have mapped the landscape of driver events and tumour evolution in IBD patients. High-resolution sequencing of dysplasia and cancers revealed that TP53 alterations emerge early in half of precancerous lesions, often via independent convergent events. Inflammation-driven neoplastic patches display suppressed Wnt-pathway activation and transcriptional rewiring, suggesting that tumour clones diverge from traditional colorectal carcinogenesis. Multi-region sequencing in human and murine models demonstrated that synchronous lesions rarely share mutations, underscoring the patchwork nature of tumour initiation against an inflamed background. These insights highlight lineage plasticity as a hallmark of CAC and point to early TP53 status as a potential biomarker for surveillance.

Inflammatory Bowel Disease and Colorectal Cancer Dynamics publication trend

The graph below shows the total number of articles in inflammatory bowel disease and colorectal cancer dynamics across all publications each year (not limited to Nature Index journals).

Technical terms

Inflammatory bowel disease (IBD): Chronic inflammatory disorders of the gastrointestinal tract, primarily ulcerative colitis and Crohn’s disease.

Colitis-associated cancer (CAC): Colorectal carcinoma arising in the context of longstanding IBD, with distinct molecular pathways from sporadic CRC.

Dysplasia: Abnormal epithelial cell growth considered a precursor to invasive carcinoma.

TP53 alteration: Mutation or loss of the tumour suppressor gene TP53, often an early event in IBD-associated neoplasia.

Wnt signalling: A key pathway regulating intestinal epithelial proliferation; rewiring away from Wnt activation is observed in inflamed mucosa.

Field cancerization: The presence of genetically altered but histologically normal tissue patches that predispose to multiple independent tumours.

Lineage plasticity: The ability of epithelial cells to adopt alternative transcriptional programmes under inflammatory stress, facilitating tumour initiation.

References

1. Integrated clinical and genomic analysis identifies driver events and molecular evolution of colitis-associated cancers. Nature Communications (2023).
2. Mutational analysis differentiating sporadic carcinomas from colitis-associated colorectal carcinomas. Cell Communication and Signaling (2024).
3. Molecular mechanisms in colitis-associated colorectal cancer. Oncogenesis (2023).
4. Smoking and colorectal neoplasia in patients with inflammatory bowel disease: Dose‐effect relationship. United European Gastroenterology Journal (2023).
5. Cumulative burden of inflammation predicts colorectal neoplasia risk in ulcerative colitis: a large single-centre study. Gut (2017).